Form 8-K

8-K — 60 DEGREES PHARMACEUTICALS, INC.

Accession: 0001213900-26-098056

Filed: 2026-09-08

Period: 2026-09-08

CIK: 0001946563

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0304862-8k_60degrees.htm (Primary)

EX-99.1 — 60 DEGREES PHARMACEUTICALS, INC. INVESTOR PRESENTATION, DATED SEPTEMBER 8, 2026 (ea030486201ex99-1.htm)

GRAPHIC (ea030486201_ex99-1img1.jpg)

GRAPHIC (ea030486201_ex99-1img2.jpg)

GRAPHIC (ea030486201_ex99-1img3.jpg)

GRAPHIC (ea030486201_ex99-1img4.jpg)

GRAPHIC (ea030486201_ex99-1img5.jpg)

GRAPHIC (ea030486201_ex99-1img6.jpg)

GRAPHIC (ea030486201_ex99-1img7.jpg)

GRAPHIC (ea030486201_ex99-1img8.jpg)

GRAPHIC (ea030486201_ex99-1img9.jpg)

GRAPHIC (ea030486201_ex99-1img10.jpg)

GRAPHIC (ea030486201_ex99-1img11.jpg)

GRAPHIC (ea030486201_ex99-1img12.jpg)

GRAPHIC (ea030486201_ex99-1img13.jpg)

GRAPHIC (ea030486201_ex99-1img14.jpg)

GRAPHIC (ea030486201_ex99-1img15.jpg)

GRAPHIC (ea030486201_ex99-1img16.jpg)

GRAPHIC (ea030486201_ex99-1img17.jpg)

GRAPHIC (ea030486201_ex99-1img18.jpg)

GRAPHIC (ea030486201_ex99-1img19.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0304862-8k_60degrees.htm · Sequence: 1

false

0001946563

2026-09-08

0001946563

SXTP:CommonStockParValue0.0001PerShareMember

2026-09-08

0001946563

SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember

2026-09-08

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION

13 OR 15(d)

OF THE SECURITIES EXCHANGE

ACT OF 1934

Date

of Report (Date of earliest event reported): September

8, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant

as specified in its charter)

Delaware

001-41719

45-2406880

(State or other jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification Number)

1025 Connecticut Avenue NW Suite 1000,

Washington, D.C.

20036

(Address of registrant’s principal executive office)

(Zip code)

(202) 327-5422

(Registrant’s telephone

number, including area code)

Not Applicable

(Former name or former

address, if changed since last report)

Check the appropriate box below if the Form

8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

SXTP

The Nasdaq Stock Market LLC

Warrants, each warrant to purchase one share of Common Stock

SXTPW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

If an emerging growth company, indicate by

check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

September 8, 2026, the Company updated its investor presentation, which it intends to use from time to time in meetings with investors, analysts

and other members of the investment community. A copy of the updated investor presentation is furnished as Exhibit 99.1 to this Current

Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item

7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934,

as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific

reference in such filing.

Cautionary Statement Regarding Forward-Looking

Statements

This Current Report on Form 8-K includes forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties

that could cause the Company’s actual results and financial position to differ materially. These risks and uncertainties include

uncertainties associated with market conditions and other risks described under the heading “Risk Factors” in the Company’s

SEC Filings on Form 10-K and Form 10-Q. The Company assumes no responsibility to update or revise any forward-looking statements to reflect

events, trends or circumstances after the date hereof.

Item 9.01 Financial Statements

and Exhibits

(a) Exhibits

Number

Description

99.1

60 Degrees Pharmaceuticals, Inc. Investor Presentation, dated September 8, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

60 DEGREES PHARMACEUTICALS, INC.

Date: September 8, 2026

By:

/s/ Geoffrey Dow

Name:

Geoffrey Dow

Title:

Chief Executive Officer and President

EX-99.1 — 60 DEGREES PHARMACEUTICALS, INC. INVESTOR PRESENTATION, DATED SEPTEMBER 8, 2026

EX-99.1

Filename: ea030486201ex99-1.htm · Sequence: 2

Exhibit 99.1

H.C. Wainwright Presentation 60 Degrees Pharmaceuticals, Inc. September 2026 Targeted therapies for vector-borne disease Investment focus A marketed antimalarial platform creates a path to potential indication expansion in babesiosis Commercial base ARAKODA® malaria prophylaxis Clinical vector Babesiosis development program Regulatory arc sNDA strategy + milestones ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 11

Disclaimer and Forward-Looking Statements DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the "Company") and does not purport to be all- inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment in the Company. The Company makes no representation or warrant as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation and contents herein are the exclusive property of the Company and may not be copied without the express prior written consent of the Company. FORWARD LOOKING STATEMENTS. This communication includes forward-looking statements based on the Company's current expectations and projections about future events. All statements contained in this communication other than statements of historical fact, including any statements regarding our future operations, are forward-looking statements. The words "believe", "may", "will", "estimate", "continue", "anticipate", "intend", "expect", "could", "would", "project", "plan", "potentially", "likely" and similar expressions are intended to identify forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Important factors that could cause our actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and otherwise provide for the commercialization of non-malaria prevention indications for Tafenoquine (Arakoda or other regimen) or Celgosivir/Australian Chestbut extracts in a timely manner, we may not be able to expand our business operations; we cannot guarantee our ability to conduct successful clinical trials; and we have no manufacturing capacity which poses the risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. As a result of these matters, changes in fact, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. In light of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Although we believe our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Unless required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 22

60° ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 3 Investment Thesis A marketed antimalarial platform creates a staged path to potential indication expansion in babesiosis. Core thesis Label expansion of ARAKODA® / tafenoquine from malaria prevention into high-need tick- borne disease opportunities, led by babesiosis. Investment setup: existing product + mechanistic rationale + human signals + near- term regulatory engagement. Potential sNDA strategy anchor 1 Commercial base ARAKODA® is already marketed for malaria prophylaxis, providing product familiarity and a safety database. 2 Lead expansion Babesiosis is the focused development opportunity, with severe, persistent, and chronic unmet-need segments. 3 Evidence package Non-clinical proof-of-concept, case- series signals, expanded access, and active studies support FDA dialogue. 4 Milestone path Interim analysis, pre-sNDA interaction, sNDA filing, and potential launch create a staged catalyst sequence. Focus: build toward a potential tafenoquine sNDA in babesiosis while leveraging the ARAKODA® platform.

Financial Snapshot Q2 2026 results + July financing / Knight conversion Q2 10-Q filed Aug. 14, 2026 COMMON OUTSTANDING/MARKET CAP ~3.51M/ ~4M Pro forma at Jul. 31: 2.659M base + 658.6k Knight conversion + 191.6k common issued in financing. Excludes pre-funded warrants. PREFERRED OUTSTANDING 68,080 Series A non-voting convertible preferred post-Knight conversion; 6% cumulative dividend. COMMON WARRANTS ~3.09M Approx. legacy/common warrants plus July Series AB warrants and placement-agent warrants. Excludes pre-funded warrants. PRE-FUNDED WARRANTS 383.1k Issued in July 2026 private placement; nominal $0.001 exercise price; shown separately from common. ARAKODA® Sales Snapshot Q2 2026 product revenue / gross profit Q2 net product revenue $208k +106% YoY Gross profit on product revenue $57k ~27% gross margin $101k Q2 2025 $208k Q2 2026 $51k Q2 2025 GP $57k Q2 2026 GP Commercial product now contributes a measurable revenue/gross-profit line while babesiosis development remains the capital driver. Financing & Runway liquidity after July financing ~$1.0M cash & equivalents June 30, 2026 ~$5.0M operating cash use 6 months ended Jun. 30 Early Oct. 2026 runway Last financing: July 31, 2026 private placement $1.0M gross • priced at $1.74 per share / pre-funded warrant + accompanying warrants 191.6k common 383.1k pre-funded 574.7k Series A 574.7k Series B Common warrant exercise price: $1.49 • PA warrants: 43.1k at $2.175 Notes: common outstanding is shown pro forma as of July 31, 2026 and excludes pre-funded warrants. Preferred outstanding reflects post-Knight conversion Series A balance. Warrant counts are approximate and exclude as-converted preferred impact. ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 44

Ticks Transmit a Widening Set of Serious Diseases in the U.S. Record tick-bite emergency room visits in 2026 underscore the rising need for targeted therapies. ER visits for tick bites RECORD LEVELS THIS YEAR (113,000+) More bites → more clinical encounters One bite can transmit multiple pathogens Examples of diseases transmitted or associated with U.S. ticks Lyme disease Anaplasmosis Relapsing fever Ehrlichiosis Rocky Mountain spotted fever Babesiosis Tularemia Powassan virus Alpha-gal syndrome Bourbon / Heartland viruses STARI Colorado tick fever Bacterial Parasitic Viral Allergic syndrome ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 55

©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 66 Critical Unmet Need in Selected Tick-Borne and Tick-Associated Diseases High burden, limited approved options, and a clear rationale for small-molecule repositioning Babesiosis Parasitic red-blood-cell infection B ≥25k claims / yr U.S. medical insurance claims associated with babesiosis² No FDA-approved treatment specifically for babesiosis Existing treatments ≤ 30% effect in relapsing disease, high mortality and long recovery time in severe cases Standard of care cure rate ≤30% in relapsing immunosuppressed patients and drug resistance UNMET NEED approved, durable treatment option Post-Treatment Lyme Disease Chronic disease following acute infection PT ≈50k–95k / yr Potential new PTLD cases in U.S.¹ No FDA-approved treatments Extended antibiotic treatment believed by patients to help but is controversial Active early trials exist; development remains sparse UNMET NEED validated treatment strategy Alpha-Gal Syndrome Red meat allergy triggered by Lone star tick bites α up to 45k / yr Potential new / diagnosed cases in U.S. Delayed reactions can be severe or life-threatening Management consists of lifestyle changes to avoid exposure to mammalian meat products No vaccine or cure; future tick bites can reactivate reactions UNMET NEED prevention + disease-modifying approach Strategic implication: a cluster of underserved indications where repositioned small molecules can shorten development timelines. ¹ CDC/NIH: ~476k Lyme diagnoses/yr; 10–20% PTLDS estimate. ² Unpublished company market research.

Portfolio August 2026 PHASES AND DEVELOPMENT STAGES PRODUCT NON-CLINICAL IND ENABLING PHASE 1 PHASE IIA Phase IIB/III REGULATORY REVIEW COMMERCIALLY AVAILABLE COMMERCIALLY SUSTAINABLE ARAKODA® (US) ZAMVIO (tafenoquine): TICK-BORNE DISEASE – VETERINARY INDICATIONS Preparing dossier for FDA meeting Tafenoquine (ARAKODA regimen): TREATMENT OF HUMAN BABESIOSIS Multiple treatment studies, interim analysis 10/6/2026 ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 77 CASTANOSPERMINE* / ALPHA GAL PLANNING FOR 2027 TQ COMBO DRUG* / BABESIOSIS PLANNING FOR 2027 REPOSITIONED DRUG* / PTLD PLANNING FOR 2027 = Completed = Next phase *Licensing arrangements or FTO analysis pending 7

8 Source: CDC signs/symptoms of babesiosis. Chronic / severe fatigue Persistent fatigue may drive prolonged recovery 8

60° ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 9 Babesiosis Treatment Gap Current regimens leave a high-need refractory segment with limited evidence and no FDA-approved options. STANDARD OF CARE TODAY First-line treatment Atovaquone + azithromycin ↓ Treatment-refractory disease Atovaquone + azithromycin + clindamycin Atovaquone + clindamycin Atovaquone/proguanil + azithromycin Atovaquone + azithromycin + clindamycin + quinine *Higher azithromycin dose may be considered WHY THIS MATTERS <30% cure rate of atovaquone-based regimens in treatment- refractory patients* 0 specific FDA-approved regimens for refractory disease listed by IDSA ! Clinical problem • Refractory patients often require prolonged, multi-drug therapy • Evidence base is limited and dominated by case experience • A repositioned oral small molecule could address the evidence and access gap Unmet need creates room for a differentiated, approvable regimen. REPOSITIONING RATIONALE New treatment option needed Tafenoquine has a plausible repositioning rationale because it is already FDA- approved for malaria prophylaxis and targets intra-erythrocytic parasites. Sets up ARAKODA® label expansion story

60° ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 10 Babesiosis: An Orphan Disease With Three Distinct Unmet Need Segments Hospitalized acute disease, refractory immunosuppressed disease, and chronic/persistent symptoms create multiple treatment opportunities. Severe Disease Hospitalization ! 1.6% mortality in immunocompetent hospitalized patients 7.0% mortality in high-risk patients • Long recovery times • Clinical urgency in older / high-risk patients UNMET NEED reduced morbidity / faster recovery Persistent Disease Immunosuppressed patients R Months–years duration in refractory cases ≤30% curative rate of atovaquone/azithromy cin* • Multiple regimens may be required • Drug resistance and relapse reported UNMET NEED durable parasite clearance Chronic Disease Poorly characterized C Fatigue and chronic symptoms 0 FDA-approved diagnostics • Babesia infection hypothesize to prolong recovery from post-infectious illness • Underserved and under-studied patient segment UNMET NEED Formal case definition, FDA-cleared diagnostics & benchmarked therapeutics

11 adult age group indicated 11 11 11 2018 US FDA approval 2019 commercially available Indicated for prophylaxis of malaria in adults 8 studies >1,100 patients 52 weeks AE rate comparable to placebo; G6PD screening required.

Tafenoquine & Babesiosis: Non-Clinical Proof of Concept Blood-smear phenotype plus SCID-mouse combination data support repositioning into Babesia. BLOOD-SMEAR PHENOTYPE (LIU ET AL.) Giemsa-stained blood smears from B. rodhaini-infected mice; 24 hours post single-dose tafenoquine vs. vehicle; H₂O₂ in vitro comparator. SCID-MOUSE COMBINATION ADDITIVITY (VYDYAM ET AL.) Atovaquone Tafenoquine Atovaquone + Tafenoquine Source: Vydyam et al., J Infect Dis. 2024;229(1):161–172. SCID mouse B. microti high-dose model. MECHANISTIC + COMBINATION TAKEAWAYS 1 Blood-smear signal Tafenoquine-treated Babesia showed a distinct RBC phenotype consistent with oxidative-stress biology. 2 Combination additivity SCID mouse data support tafenoquine + atovaquone activity and durability beyond either agent alone. 3 Clinical bridge Distinct biology plus combination activity supports the refractory babesiosis repositioning strategy. Supports move from antimalarial product → Babesia combination development ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 12

13 13 13 Treatment-Refractory Babesiosis: Human Case-Series Signal Tafenoquine combinations cured 4 of 4 immunosuppressed patients when administered concurrently for >8 weeks. 13 >8 wks concurrent tafenoquine + atovaquone + antibiotic combinations 1 Human signal Cure observed in difficult-to-treat immunosuppressed patients with refractory B. microti disease. 2 Combination context Tafenoquine was administered with atovaquone-based therapy and antibiotics. 3 Regulatory use Provides potentially supportive data for an NDA package 4 Development rationale Provided the rationale for the Company's tafenoquine babesiosis development plan

Babesiosis Could Triple the ARAKODA® Asset Opportunity Patient exclusivity creates two ways to expand the same marketed antimalarial platform: treated patients and treatment-course value. PATIENT CASELOAD OPPORTUNITY VALUE OPPORTUNITY AT CURRENT WAC Maximum cumulative addressable market (2026Q3–2035) Malaria Prevention trips / patients 450,000 Treatment of Babesiosis trips / patients 350,000 Max possible prescriptions for three weeks of travel* Max possible patients treated post-FDA approval** Maximum WAC-value opportunity $90M Malaria prevention $180M Babesiosis treatment $270M Combined asset 3× Same product platform; babesiosis opportunity adds treatment demand and longer-course economics. Value reflects current WAC Pursuit of babesiosis potentially triples the value of the asset.

15 Tafenoquine + SOC vs placebo + SOC TQ dose: 200 mg × 4, then 200 mg weekly for 4 weeks Primary: TTSCR* 200 mg weekly following the load through Day 90 *TTSCR = time to sustained clinical resolution; TTMC = time to molecular cure. 15 15 15 NAT test used to define cure

16 Objective: Align with FDA on NAT as a relapse surrogate and a confirmatory-study path that can support indication expansion. 16 16 16

17 Sources: FDA press announcement and supplemental approval materials for Wellcovorin/leucovorin calcium (Mar. 2026). 17 17 17

18 Hospital study efficacy plus expanded access cure data could support lower risk regulatory approval pathway 18 18 18 Derisked Regulatory Pathway: Regular sNDA

19 Potential PDUFA date with priority review 19 OTHER ANTICIPATED MILESTONES New product collaborations • market updates • other product research updates Potential PDUFA date with priority review 19 OTHER ANTICIPATED MILESTONES New product collaborations • market updates • other product research updates Potential PDUFA date with priority review 19 19

GRAPHIC

Filename: ea030486201_ex99-1img1.jpg · Sequence: 3

Binary file (288606 bytes)

Download ea030486201_ex99-1img1.jpg

GRAPHIC

Filename: ea030486201_ex99-1img2.jpg · Sequence: 4

Binary file (452605 bytes)

Download ea030486201_ex99-1img2.jpg

GRAPHIC

Filename: ea030486201_ex99-1img3.jpg · Sequence: 5

Binary file (368464 bytes)

Download ea030486201_ex99-1img3.jpg

GRAPHIC

Filename: ea030486201_ex99-1img4.jpg · Sequence: 6

Binary file (420657 bytes)

Download ea030486201_ex99-1img4.jpg

GRAPHIC

Filename: ea030486201_ex99-1img5.jpg · Sequence: 7

Binary file (370645 bytes)

Download ea030486201_ex99-1img5.jpg

GRAPHIC

Filename: ea030486201_ex99-1img6.jpg · Sequence: 8

Binary file (371878 bytes)

Download ea030486201_ex99-1img6.jpg

GRAPHIC

Filename: ea030486201_ex99-1img7.jpg · Sequence: 9

Binary file (316435 bytes)

Download ea030486201_ex99-1img7.jpg

GRAPHIC

Filename: ea030486201_ex99-1img8.jpg · Sequence: 10

Binary file (456414 bytes)

Download ea030486201_ex99-1img8.jpg

GRAPHIC

Filename: ea030486201_ex99-1img9.jpg · Sequence: 11

Binary file (355503 bytes)

Download ea030486201_ex99-1img9.jpg

GRAPHIC

Filename: ea030486201_ex99-1img10.jpg · Sequence: 12

Binary file (356281 bytes)

Download ea030486201_ex99-1img10.jpg

GRAPHIC

Filename: ea030486201_ex99-1img11.jpg · Sequence: 13

Binary file (387432 bytes)

Download ea030486201_ex99-1img11.jpg

GRAPHIC

Filename: ea030486201_ex99-1img12.jpg · Sequence: 14

Binary file (411921 bytes)

Download ea030486201_ex99-1img12.jpg

GRAPHIC

Filename: ea030486201_ex99-1img13.jpg · Sequence: 15

Binary file (346025 bytes)

Download ea030486201_ex99-1img13.jpg

GRAPHIC

Filename: ea030486201_ex99-1img14.jpg · Sequence: 16

Binary file (370415 bytes)

Download ea030486201_ex99-1img14.jpg

GRAPHIC

Filename: ea030486201_ex99-1img15.jpg · Sequence: 17

Binary file (339275 bytes)

Download ea030486201_ex99-1img15.jpg

GRAPHIC

Filename: ea030486201_ex99-1img16.jpg · Sequence: 18

Binary file (278147 bytes)

Download ea030486201_ex99-1img16.jpg

GRAPHIC

Filename: ea030486201_ex99-1img17.jpg · Sequence: 19

Binary file (307023 bytes)

Download ea030486201_ex99-1img17.jpg

GRAPHIC

Filename: ea030486201_ex99-1img18.jpg · Sequence: 20

Binary file (270263 bytes)

Download ea030486201_ex99-1img18.jpg

GRAPHIC

Filename: ea030486201_ex99-1img19.jpg · Sequence: 21

Binary file (265770 bytes)

Download ea030486201_ex99-1img19.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 27

v3.26.1

Cover

Sep. 08, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 08, 2026

Entity File Number

001-41719

Entity Registrant Name

60 DEGREES PHARMACEUTICALS, INC.

Entity Central Index Key

0001946563

Entity Tax Identification Number

45-2406880

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1025 Connecticut Avenue NW Suite 1000,

Entity Address, City or Town

Washington

Entity Address, State or Province

Entity Address, Postal Zip Code

20036

City Area Code

202

Local Phone Number

327-5422

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

SXTP

Security Exchange Name

NASDAQ

Warrants, each warrant to purchase one share of Common Stock

Title of 12(b) Security

Warrants, each warrant to purchase one share of Common Stock

Trading Symbol

SXTPW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=SXTP_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=SXTP_WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: